| | Variables | Advanced fibrosis, N = 42 | No advanced fibrosis, N = 135 | value |
| | Age at LT, years (IQR) | 53 (44–60) | 56 (50–61) | 0.061 | | Age at TE, years (IQR) | 58 (51–64) | 61 (54–65) | 0.159 | | Donor age, years | 59 (46–70) | 57 (43–67) | 0.806 | | Male, % (n) | 71.4 (30) | 67.4 (89) | 0.768 |
| | Cause of liver disease, % (n) | | Autoimmune liver disease | 7.1 (3) | 12.6 (17) | 0.578 | | NAFLD | 0 | 0.7 (1) | | Alcoholic liver disease | 40.5 (17) | 29.6 (40) | | HCV | 4.8 (2) | 3.0 (4) | | Others | 47.6 (20) | 54.1 (73) |
| | BMI, kg/m2 (IQR) | 29.35 (23–32) | 27 (24–32) | 0.738 |
| | BMI category, % (n) | | | | | Normal <25 | 40.5 (17) | 34.8 (47) | 0.487 | | Overweight 25–29.9 | 19.0 (8) | 32.6 (44) | | Obese ≥30 | 40.5 (17) | 32.6 (44) | | Donors BMI, kg/m2 (IQR) | 26.54 (25–29) | 26 (24–28) | 0.312 |
| | Donors BMI category, % (n) | | | | | Normal <25 | 31.0 (13) | 39.3 (53) | 0.620 | | Overweight 25–29.9 | 52.4 (22) | 46.7 (63) | | Obese ≥30 | 16.7 (7) | 14.1 (19) |
| | Hypertension, % (n) | 76.2 (32) | 61.5 (83) | 0.119 | | Diabetes, % (n) | 45.2 (19) | 37.0 (50) | 0.441 | | Thrombocytes x109/L | 145 (106–221) | 170 (144–221) | 0.082 | | Glucose, mmol/L (IQR) | 6.2 (6–8) | 6.1 (5–7) | 0.240 | | Total bilirubin, mg/dL (IQR) | 18 (14–26) | 15 (12–20) | 0.005 | | ALT, U/L (IQR) | 33 (24–60) | 26 (18–35) | <0.001 | | AST, U/L (IQR) | 43 (25–72) | 26 (21–35) | <0.001 | | GGT, U/L (IQR) | 83 (40–173) | 31 (21–65) | <0.001 | | Triglyceride, mmol/L (IQR) | 1.43 (1.1–1.9) | 1.2 (0.9–1.8) | 0.066 | | Total cholesterol, mmol/L (IQR) | 5.1 (4.3–5.5) | 5.1 (4.5–6) | 0.282 | | LDL, mmol/L (IQR) | 3.1 (2.6–3.7) | 2.9 (2.3–3.4) | 0.048 | | HDL, mmol/L (IQR) | 1.2 (1–1.7) | 1.3 (1.1–1.6) | 0.429 | | CRP, mg/L (IQR) | 4.4 (2–7) | 3.1 (1.8–5.6) | 0.368 | | CAP, dB (IQR) | 285 (213–341) | 277 (222–315) | 0.469 |
| | Immunosuppression, % (n) | | Tacrolimus | 50.0 (21) | 77.0 (104) | <0.001 | | Cyclosporine | 52.5 (21) | 23.3 (31) | | Prednisone | 2.4 (1) | 5.2 (7) | | mTOR inhibitor | 2.4 (1) | 0 | | Mycophenolate mofetil | 78.6 (33) | 65.2 (88) | | Azathioprine | 2.4 (1) | 1.5 (2) |
| | Time from LT to TE, years (IQR) | 5 (3–6) | 4 (2–6) | 0.015 |
|
|
LT, liver transplantation; NAFLD, nonalcoholic fatty liver disease; HCV, hepatitis C virus infection; BMI, body mass index; AST, serum aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; CRP, C-reactive protein; CAP, controlled attenuation parameter; TE, transient elastography. |
